小隐静脉与臂静脉作为上肢缺血旁路移植物的应用
该回顾性病例系列研究纳入2010年至2018年47例接受上肢旁路移植的患者,其中30例使用臂静脉、17例使用小隐静脉(SSV)。12个月一期通畅率SSV组87%、臂静脉组75%(P=0.8),36个月分别为63%和75%(P=0.9);36个月二期通畅率两组均为100%(P=0.4)。结论认为臂静脉或SSV作为旁路移植物可行,死亡率和并发症率合理,结果与大隐静脉相当。
要点
- 上肢旁路移植可选用臂静脉或小隐静脉作为自体移植物。
- 12个月一期通畅率SSV组87%、臂静脉组75%,差异无统计学意义。
- 36个月二期通畅率两组均为100%,仅1例大截肢、2例小截肢。
核心结论
- 使用臂静脉或小隐静脉作为旁路移植物行上肢血运重建,死亡率和并发症率合理,结果与大隐静脉相当。
研究设计与样本
- 回顾性分析2010年1月至2018年2月单中心连续收集的病例系列,共47例上肢旁路移植患者,其中SSV组17例、臂静脉组30例。
主要发现
- 12个月一期通畅率SSV组87%、臂静脉组75%(P=0.8),36个月分别为63%和75%(P=0.9)。
- 36个月二期通畅率臂静脉组100%、SSV组100%(P=0.4)。
- 1例患者行大截肢,2例行长截肢。
- 适应证包括急性缺血12例、慢性缺血35例,病因涵盖急慢性创伤、医源性干预后遗症、外周动脉疾病、血栓闭塞性脉管炎及透析通路相关并发症。
临床怎么用
- 在缺乏大隐静脉或不适用的上肢缺血病例中,可考虑采用臂静脉或小隐静脉作为旁路移植物的替代选择。
局限性
- 回顾性单中心病例系列,样本量有限(47例),部分亚组样本量小可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bypass in the upper extremity is a rare procedure mainly performed for chronic ischemia, trauma, or hemodialysis access complications. Feasibility and success of use of the arm vein and small saphenous vein (SSV) for autologous vein bypass have been reported in peripheral artery bypass procedures. There are very few reports on the use of alternative veins in upper extremity bypass. We report our experience with arm vein and SSV as a graft source in upper extremity arterial disease. METHODS: Retrospective analysis of a consecutively collected case series in an academic tertiary referral center from January 2010 to February 2018. Study end points were primary patency, secondary patency, limb salvage, and survival. RESULTS: In total, 47 patients were treated with upper extremity bypass either using the SSV (n = 17) or arm veins (n = 30). Indications were either acute (n = 12) or chronic ischemia (n = 35) caused by acute (n = 8) and chronic (n = 9) trauma, sequela of iatrogenic interventions (n = 4), peripheral artery disease (n = 14), thrombangiitis obliterans (n = 3), and dialysis-access-related complications (n = 9). An arm vein was used in 30 and the SSV in 17 patients. Primary patency after 12 months was 87% with the SSV and 75% with an arm vein (P = 0.8) and 63% and 75% after 36 months (P = 0.9). Secondary patency were 100% with an arm vein and 100% with the SSV after 36 months (P = 0.4). One patient had to undergo major amputation and 2 minor amputations. CONCLUSIONS: Arm vein revascularization using the primarily arm vein or SSV as a bypass conduit can be performed with reasonable mortality and morbidity rates and provide good results comparable with the greater saphenous vein.
引用
- Nierlich P, Enzmann FK, Dabernig W, et al. Small Saphenous Vein and Arm Vein as Bypass Grafts for Upper Extremity Ischemia. Ann Vasc Surg. 2019. PMID: 31075469. doi:10.1016/j.avsg.2019.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。